Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
| Revenue (Most Recent Fiscal Year) | $80.00M |
| Net Income (Most Recent Fiscal Year) | $-65.00M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.33 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.57 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -125.46% |
| Net Margin (Trailing 12 Months) | -126.49% |
| Return on Equity (Trailing 12 Months) | -27.36% |
| Return on Assets (Trailing 12 Months) | -21.06% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.10 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.10 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.93 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.53 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.13 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.46 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 55.34M |
| Free Float | 51.80M |
| Market Capitalization | $156.05M |
| Average Volume (Last 20 Days) | 0.36M |
| Beta (Past 60 Months) | 0.95 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.39% |
| Percentage Held By Institutions (Latest 13F Reports) | 48.03% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |